The global pharmaceutical sterility testing market size is anticipated to register a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to Government investments in the healthcare industry, increasing R&D activities and number of drug launches, and rising focus on quality and sterility.
Sterility testing is a technique primarily used to check the presence of microorganisms in biological parenteral that are intended for human use. Sterility testing is necessary process to ensure that all biopharmaceutical products, medical devices, and pharmaceutical products are free from microorganisms. Fungistasis and bacteriostasis tests are the two popular names for the sterility process. The pharmaceutical industry has benefited due to increase in public awareness of various threats from microorganisms. Over the years, the industry has been constantly developing several drugs and testing devices to eliminate the contamination of these from bacteria and others, which lead to discarding of non-sterile medical devices. Sterility testing is used in both pharmaceutical manufacturing and bioproduction. Moreover, the pharmaceuticals sterility testing is mostly used for research and development as well as to ensure the safety of manufactured drugs. It is a crucial step for every manufacturer to ensure that drugs are safe to use.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing investments in R&D to develop innovative products and rising demand for innovative testing devices are projected to drive the market growth during the forecast period.
- Accelerating drug approval from various regulatory bodies especially in developed regions in order to meet the growing healthcare demand act a major factor propelling the market growth.
- Increasing number of patients suffering from cardiovascular disorders such as heart failure, heart attack, high blood pressure, and cancer-related diseases is expected to drive the market growth.
- Lack of development of advanced medical facilities and poor establishment of diagnostic centers especially in the low-income countries are expected to restrict the market growth.
- Increasing investments from developing economies such as China and India for developing cost effective medications are estimated to create lucrative opportunities for the market expansion.
Scope of the Report
The report on the global pharmaceutical sterility testing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes
|
Details
|
Report Title
|
Pharmaceutical Sterility Testing Market- Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
Base Year
|
2020
|
Historic Data
|
2018–2019
|
Forecast Period
|
2021–2028
|
Segmentation
|
Types (In-house and Outsourcing), Test Types (Sterility Testing, Bioburden Testing, Bacterial Endotoxin Testing), End-use (Compounding Pharmacies, Medical Devices Companies, Pharmaceutical Companies, and Others), and Samples (Sterile Drugs, Medical Devices, and Biologics & Therapeutics)
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
Key Players Covered in the Report
|
SGS SA; Toxikon, Inc.; Pace Analytical Services, LLC; Boston Analytical; Charles River Laboratories International, Inc.; and Nelson Laboratories
|
Market Segment Insights
Outsourcing segment is expected to account for a key market share
Based on types, the pharmaceutical sterility testing market is bifurcated into in-house and outsourcing. The outsourcing segment is expected to account for a key share of the market during the forecast period owing to factors such as saving time and cost by reducing the need of training personnel and purchase of sterility testing equipment. The option of outsourcing sterility testing is appealing due to its cost efficiency to provide the services. Some businesses lack the necessary resources to perform high-quality sterility tests, this tends to outsource these services.
Bacterial endotoxin testing segment is expected to constitute a major key share
On the basis of test types, the market is segmented into sterility testing, bioburden testing, and bacterial endotoxin testing. The bacterial endotoxin testing segment is expected to constitute a key share of the market during the forecast period owing to the ongoing technological advancements. On the other hand, the sterility testing and bioburden testing segment in combined is expected to register a significant growth during the forecast period. The segment growth is expected due to growing emphasis on product quality as well as an increase in the number of drug and medical device launches.
Pharmaceutical companies segment is expected to rapid growth
Based on end-users, the pharmaceutical sterility testing market is segmented into compounding pharmacies, medical devices companies, pharmaceutical companies, and others. The other segment consists of hospitals, biopharmaceuticals, clinics, and research labs. The others segment is expected to represent a key share of the market during the forecast period owing to increasing R&D activities, outsourcing services, and rise in innovative biopharmaceutical products. However, the pharmaceutical companies segment is anticipated to expand at a rapid pace during the forecast period owing to regulatory requirement to conduct sterility testing for each batch release to ensure product safety.
Sterile drugs segment is expected to constitute a large market share
In terms of samples, the market is segmented into sterile drugs, medical devices, and biologics & therapeutics. The sterile drugs segment is expected to constitute a large share of the market during the forecast period owing to high adoption of several techniques, which are widely adopted for product safety. On the other hand, the biologic 7 therapeutics segment is anticipated to expand at a robust growth rate during the forecast period due to technological advancements in sterility testing procedures, biosimilars, vaccines, and other biologics, as well as regulatory standards to ensure the sterility of biologics and therapeutics.
North America is anticipated to dominate the market
On the basis of regions, the pharmaceutical sterility testing market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market CAGR during the forecast period owing to the presence of a large number of global and domestic players in this region. On the other hand, the market in Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to increasing harmonization of the regulatory standards with the ICH standards in developing nations. Furthermore, many developing economies in the region such as China and India are taking steps to improve the domestic pharmaceutical market and are encouraging multinational firms to set up operations in the region. Such initiatives are certainly leading to the regional market development.
Segments
Segments Covered in the Report
The global pharmaceutical sterility testing market has been segmented on the basis of
Types
Test Types
- Sterility Testing
- Bioburden Testing
- Bacterial Endotoxin Testing
End-users
- Compounding Pharmacies
- Medical Devices Companies
- Pharmaceutical Companies
- Others
Samples
- Sterile Drugs
- Medical Devices
- Biologics & Therapeutics
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- SGS SA
- Toxikon, Inc.
- Pace Analytical Services, LLC
- Boston Analytical
- Charles River Laboratories International, Inc.
- Nelson Laboratories
Competitive Landscape
Key players competing in the pharmaceutical sterility testing market include SGS SA; Toxikon, Inc.; Pace Analytical Services, LLC; Boston Analytical; Charles River Laboratories International, Inc.; and Nelson Laboratories.
Regional expansions, mergers, and acquisitions are some of the widely adopted business strategies by these players to increase their market shares. For instance, On July 2015, Charles River Laboratories bought Celsis International Ltd. to expand its microbiology testing capability.
